CAPS Rating: 2 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.


Player Avatar zzlangerhans (99.85) Submitted: 10/24/2011 1:41:31 PM : Underperform Start Price: $8.29 EXAS Score: +11.98

Exact's share price seems to be getting ahead of itself yet again as the Cologuard trial enters the early stages of an enrollment process that will likely extend at least another 12 months. That means topline data is unlikely before 2013, and the stock remains vulnerable to broad market declines. Personally, I believe we're headed for a doozy of a decline within the next few months. 435M is a hefty market cap for a company whose pipeline consists of a single unproven laboratory assay.

Featured Broker Partners